Drug Resistance, Neoplasm

"Drug Resistance, Neoplasm" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.

Descriptor ID	D019008
MeSH Number(s)	G07.690.773.984.395
Concept/Terms	Drug Resistance, Neoplasm Drug Resistance, Neoplasm Resistance, Antineoplastic Agent Resistance, Antineoplastic Drug Drug Resistance, Antineoplastic Neoplasm Drug Resistance Antineoplastic Agent Resistance Antineoplastic Drug Resistance Antibiotic Resistance, Neoplasm Antibiotic Resistance, Neoplasm

Below are MeSH descriptors whose meaning is more general than "Drug Resistance, Neoplasm".

Biological Sciences [G]
Physiological Phenomena [G07]
Pharmacological and Toxicological Phenomena [G07.690]
Pharmacological Phenomena [G07.690.773]
Drug Resistance [G07.690.773.984]
Drug Resistance, Neoplasm [G07.690.773.984.395]

Below are MeSH descriptors whose meaning is related to "Drug Resistance, Neoplasm".

Below are MeSH descriptors whose meaning is more specific than "Drug Resistance, Neoplasm".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Drug Resistance, Neoplasm" by people in this website by year, and whether "Drug Resistance, Neoplasm" was a major or minor topic of these publications.

Bar chart showing 134 publications over 22 distinct years, with a maximum of 13 publications in 2021

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	0	1	1
2002	1	1	2
2003	1	2	3
2004	1	1	2
2005	1	4	5
2007	2	1	3
2008	1	3	4
2009	1	6	7
2010	3	7	10
2011	2	6	8
2012	0	2	2
2013	4	4	8
2014	8	3	11
2015	5	3	8
2016	7	5	12
2017	5	3	8
2018	4	6	10
2019	3	5	8
2020	1	5	6
2021	4	9	13
2022	0	1	1
2023	1	1	2

Below are the most recent publications written about "Drug Resistance, Neoplasm" by people in Profiles.

Xue T, Fei S, Gu J, Li N, Zhang P, Liu X, Thompson PR, Zhang X. Inhibiting MEK1 R189 citrullination enhances the chemosensitivity of docetaxel to multiple tumour cells. Philos Trans R Soc Lond B Biol Sci. 2023 11 20; 378(1890):20220246.

View in: PubMed
Nuvola G, Santoni M, Rizzo M, Rosellini M, Mollica V, Rizzo A, Marchetti A, Battelli N, Massari F. Adapting to hormone-therapy resistance for adopting the right therapeutic strategy in advanced prostate cancer. Expert Rev Anticancer Ther. 2023 06; 23(6):593-600.

View in: PubMed
Sayin S, Rosener B, Li CG, Ho B, Ponomarova O, Ward DV, Walhout AJM, Mitchell A. Evolved bacterial resistance to the chemotherapy gemcitabine modulates its efficacy in co-cultured cancer cells. Elife. 2023 02 03; 12.

View in: PubMed
Bugide S, Edwards YJK, Gupta R, Green MR, Wajapeyee N. CBX5 loss drives EGFR inhibitor resistance and results in therapeutically actionable vulnerabilities in lung cancer. Proc Natl Acad Sci U S A. 2023 01 24; 120(4):e2218118120.

View in: PubMed
Lengert AVH, Pereira LDNB, Cabral ERM, Gomes INF, Jesus LM, Gon?alves MFS, Rocha AOD, Tassinari TA, Silva LSD, Laus AC, Vidal DO, Pinto MT, Reis RM, Lopes LF. Potential New Therapeutic Approaches for Cisplatin-Resistant Testicular Germ Cell Tumors. Front Biosci (Landmark Ed). 2022 08 16; 27(8):245.

View in: PubMed
Karakasheva TA, Gabre JT, Sachdeva UM, Cruz-Acu?a R, Lin EW, DeMarshall M, Falk GW, Ginsberg GG, Yang Z, Kim MM, Diffenderfer ES, Pitarresi JR, Li J, Muir AB, Hamilton KE, Nakagawa H, Bass AJ, Rustgi AK. Patient-derived organoids as a platform for modeling a patient's response to chemoradiotherapy in esophageal cancer. Sci Rep. 2021 10 29; 11(1):21304.

View in: PubMed
Manne RK, Agrawal Y, Malonia SK, Banday S, Edachery S, Patel A, Kumar A, Shetty P, Santra MK. FBXL20 promotes breast cancer malignancy by inhibiting apoptosis through degradation of PUMA and BAX. J Biol Chem. 2021 10; 297(4):101253.

View in: PubMed
Khoshkenar P, Lowry E, Mitchell A. Rapid signaling reactivation after targeted BRAF inhibition predicts the proliferation of individual melanoma cells from an isogenic population. Sci Rep. 2021 07 29; 11(1):15473.

View in: PubMed
Cong K, Peng M, Kousholt AN, Lee WTC, Lee S, Nayak S, Krais J, VanderVere-Carozza PS, Pawelczak KS, Calvo J, Panzarino NJ, Turchi JJ, Johnson N, Jonkers J, Rothenberg E, Cantor SB. Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency. Mol Cell. 2021 08 05; 81(15):3128-3144.e7.

View in: PubMed
van de Donk NWCJ, Usmani SZ, Yong K. CAR T-cell therapy for multiple myeloma: state of the art and prospects. Lancet Haematol. 2021 Jun; 8(6):e446-e461.

View in: PubMed

People

Explore

Similar Concepts

Top Journals